Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) just unveiled an update.
CANbridge Pharmaceuticals Inc. has announced additional details regarding the write-off of its right of use assets related to its office and laboratory in Boston, U.S., as part of its downsizing efforts. The lease liabilities remained recognized in the financial statements as of December 31, 2024, due to the lease contract’s legal binding until February 28, 2025. Additionally, the company provided updates on its share schemes, detailing the exercise of options and vesting of RSUs under its Pre-IPO Equity Incentive Plan and Post-IPO RSU Scheme, reflecting ongoing employee incentives and stock management strategies.
The most recent analyst rating on (HK:1228) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare diseases and targeted cancers. The company operates primarily in the pharmaceutical industry, with a market focus on addressing unmet medical needs in these specialized areas.
Average Trading Volume: 15,106,585
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.18B
See more insights into 1228 stock on TipRanks’ Stock Analysis page.